Nabeel Ahmed

Mr. Nabeel Ahmed

School of Pharmacy, School of Rehabilitation, International Education School, Kunming Medical University, Kunming, Yunnan, China
orcid
Interests in Pharmacology, CAR Therapy, Oncology, Network Ph...

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
HHHafiz Rashid Hussain
Hafiz Rashid Hussain
Nabeel AhmedNabeel Ahmed
Nabeel Ahmed
MAMuhammad Waseem Akram
Muhammad Waseem Akram
FGFaisal Gulzar
Faisal Gulzar
JKJawad Akbar Khan
Jawad Akbar Khan
MRMuneeb Ur Rahman
Muneeb Ur Rahman
Introduction: Every one in seven people with Type-I or Type-II diabetes suffers from fear of hypoglycemia (FOH). Its impact on quality of life, glycemic control, and health outcomes is well studied. However, its relationship with sleep quality remains underexplored, particularly in developing societies. We hypothesize that FOH is a key predictor of sleep quality in Type-I and Type-II patients with diabetes and, therefore, needs detailed investigation.Methods: A multicentric study was conducted across five cities and six centers of Punjab. Data from 310 diabetes patients were analyzed using the Hypoglycemia Fear Survey-II (HFS-II) Scale and the Pittsburgh Sleep Quality Index (PSQI). Statistical analyses explored subgroup variations, correlations, regression models, and receiver operator curve (ROC) estimation.Results: The study reports 57.70% of patients with poor sleep among whom 47% had elevated FOH. Sleep quality, age, gender, diabetes duration, and insulin route significantly correlated with FOH (p < 0.05), while glycemic control and insulin use did not. Binary logistics regression showed that for every one-unit increase in FOH, the odds of experiencing poor sleep increased by approximately 3.7% (p < 0.001; OR 1.037). Five out of seven sleep components (sleep quality, efficiency, disturbance, medication use, and daytime dysfunction) were significantly related to FOH. We hypothesize that FOH might specifically influence the quality rather than the initiation or termination of the sleep cycle. ROC analysis revealed that HFS-II may be better at diagnosing poor sleep in patients than by chance (p < 0.001) with an AUC of 0.691.Conclusion: FOH is a key predictor of sleep quality among patients with diabetes. Healthcare providers should prioritize patient education targeting common FOH concerns and assess patients with disturbed sleep for elevated FOH levels, as it may contribute to sleep disturbances.

7 February 2025 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
Shairyar AfzalShairyar Afzal
Shairyar Afzal
MBMishal Bajwa
Mishal Bajwa
Nabeel AhmedNabeel Ahmed
Nabeel Ahmed
JJJawaria Jabeen
Jawaria Jabeen
MHMian Shahzeb Haroon
Mian Shahzeb Haroon
Zikria SaleemZikria Saleem
Zikria Saleem
Background: Consistent and timely access to antibiotics is a hallmark of an antimicrobial stewardship program (ASP) and can be achieved through good procurement practices. However, flawed procurement modules result in poor antibiotic supply management within health facilities of low- and middle-income countries (LMICs), including Pakistan, exacerbating antimicrobial resistance (AMR). This study seeks to understand hospital pharmacists’ perspectives on the antibiotic procurement process, its efficiency in ensuring consistent access to antibiotics, and the role of clinical pharmacists in rational procurement. Methods: Semi-structured interviews with 24 purposively selected hospital pharmacists from secondary healthcare facilities in Punjab, Pakistan, were conducted utilizing a qualitative case study methodology. Data analysis was conducted using MAXQDA 2024 software, following a thematic analysis technique using a codebook approach to thematic analysis. Results: The study identified five central themes: (1) The state of antibiotic use in hospitals is characterized by a lack of antibiotic use policy, resulting in mostly empirical and irrational prescribing practices. (2) Medicine availability significantly influences prescribing decisions, often taking precedence over clinical needs. (3) The procurement process, although structured, is flawed owing to rigid adherence to the Standard Medicine List (SML). (4) Rationality in procurement is compromised by disregard for AMR, with decisions driven more by cost and demand than clinical evidence. (5) The clinical acumen of pharmacists is underutilized in procurement due to multifarious barriers. Conclusion: Antibiotic procurement is the mainstay of implementing an ASP in hospitals. This study elucidates significant policy, practice, and education gaps regarding antibiotic use and procurement in Pakistan. There is a critical need for comprehensive antibiotic policies, including a revision in SML, enhancing pharmacist authority in procurement decisions, more rational prescribing, and ensuring access to antibiotics through more informed and data-driven processes to combat AMR effectively.

17 August 2024 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
JJJawaria Jabeen
Jawaria Jabeen
Nabeel AhmedNabeel Ahmed
Nabeel Ahmed
ZSZunaira Shahzad
Zunaira Shahzad
MSMaida Shahid
Maida Shahid
Taseer AhmadTaseer Ahmad
Taseer Ahmad
(1) Background: The SARS-CoV-2 papain-like protease (PLpro) remains an underexplored antiviral target so far. The reduced efficacy of approved treatments against novel variants highlights the importance of developing new agents. This review aims to provide a comprehensive understanding of phytochemicals as inhibitors of PLpro, identify gaps, and propose novel insights for future reference. (2) Methods: A thorough literature search was conducted using Google Scholar, ScienceDirect, and PubMed. Out of 150 articles reviewed, 57 met inclusion criteria, focusing on SARS-CoV-2 PLpro inhibitors, excluding studies on other coronaviruses or solely herbal extracts. Data were presented class-wise, and phytochemicals were grouped into virtual, weak, modest, and potential inhibitors. (3) Results: Approximately 100 phytochemicals are reported in the literature as PLpro inhibitors. We classified them as virtual inhibitors (70), weak inhibitors (13), modest inhibitors (11), and potential inhibitors (6). Flavonoids, terpenoids, and their glycosides predominated. Notably, six phytochemicals, including schaftoside, tanshinones, hypericin, and methyl 3,4-dihydroxybenzoate, emerged as potent PLpro inhibitors with favorable selectivity indices and disease-mitigation potential; (4) Conclusions: PLpro stands as a promising therapeutic target against SARS-CoV-2. The phytochemicals reported in the literature possess valuable drug potential; however, certain experimental and clinical gaps need to be filled to meet the therapeutic needs.

20 February 2026 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
Nabeel AhmedNabeel Ahmed
Nabeel Ahmed
JJJawaria Jabeen
Jawaria Jabeen
MRMalja Rehman
Malja Rehman
SNSafa Noor
Safa Noor
STSana Tahseen
Sana Tahseen
LLLechun Lyn
Lechun Lyn

19 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Nabeel AhmedNabeel Ahmed
Nabeel Ahmed
JJJawaria Jabeen
Jawaria Jabeen
SNSafa Noor
Safa Noor
MRMalja Rehman
Malja Rehman
STSana Tahseen
Sana Tahseen
Zhiwei HuZhiwei Hu
Zhiwei Hu
Background: For almost two decades now, chimeric antigen receptor-natural killer cells (CAR-NK) have been investigated in pre-clinical breast cancer models, yet clinical evidence on efficacy remains scarce. This meta-analysis provides pooled evidence of pre-clinical CAR-NK effectiveness and safety in breast cancer and an overview of current clinical trials to support clinical translation. Methods: Following PRISMA guidelines and a registered protocol (PROSPERO, CRD420251131530), PubMed, Web of Science, and Scopus were searched up to 30 June 2025 for pre-clinical CAR-NK studies in breast cancer. Clinical studies were retrieved from clinicaltrials.gov and the International Clinical Trial Registry Platform (ICTRP) up to 1 March 2026. Pre-clinical studies without in vivo data or non-human CAR-NK cells were excluded. Primary outcomes were tumor burden (ratio of means, ROMs) and survival (median survival ratio, MSR). Data were analyzed in JASP™ and risk of bias (RoB) was assessed using SYRCLE’s tool. Results: Fourteen pre-clinical studies (38 CAR-NK treatment groups targeting EGFR, HER2, tissue factor, CD70, mesothelin, or folate receptor, with peripheral blood as the primary NK source, and a 5–10 million cell dose) and 11 early-phase clinical studies (targeting HER2, TROP2, PD-L1, MUC1, or NKG2D ligands under ongoing investigation) were included. In pooled pre-clinical analysis, CAR-NK significantly reduced tumor burden against untreated and unmodified/mock controls (ROM 0.311 [0.22–0.44] and 0.42 [0.33–0.53], p < 0.001, respectively). Survival was also prolonged significantly (MSR 1.47 [1.15–1.87], p = 0.010 vs. untreated; 1.30 [1.09–1.60], p = 0.007 vs. unmodified/mock NK cells). Subgroup analyses indicated improved efficacy with peripheral blood source and 5–10 M dosing. No treatment-related toxicities were reported. CAR-NK persistence was generally higher than unmodified/mock NK cells. Discussion and Conclusions: Significant heterogeneity was observed in ROM analysis which the multi-level meta-analysis configured as intra-study interventional variability. There was moderate RoB in pre-clinical studies. Published results from clinical trials remain limited, highlighting early stages of investigation. Overall, CAR-NK therapy demonstrated consistent pre-clinical efficacy and safety, supporting further translational and clinical evaluation in breast cancer.

29 November 2024
Verified
Book Chapter
Closed access
Nabeel AhmedNabeel Ahmed
Nabeel Ahmed
ASAimen Sajid
Aimen Sajid
TATaseer Ahmad
Taseer Ahmad
MSMuhammad Ajmal Shah
Muhammad Ajmal Shah
ASAbdul Jabbar Shah
Abdul Jabbar Shah